TSX lower as gold rally takes a breather
RA’ANANA, Israel - Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) announced Tuesday it has received a $27 million binding purchase order from a national ministry of health in Africa for its FDA-cleared ART100 systems. The order value represents nearly 85% of the company’s current market capitalization of $31.77 million, according to InvestingPro data.
The order, secured through Inspira’s exclusive distribution partner, will initiate an immediate nationwide deployment program across the African nation. According to the company, full contractual payment is scheduled for completion during 2025. The company maintains a healthy liquidity position with a current ratio of 2.02, as reported by InvestingPro.
This purchase represents the second major order for Inspira in recent months, bringing the company’s total binding purchase orders for 2025 to $49.5 million. The ART100 system is approved for cardiopulmonary bypass in the U.S. and for ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S.
"This $27 million government purchase order is a strategic breakthrough that is a validation of our commercial model," said Dagi Ben-Noon, CEO of Inspira Technologies, in the press release.
The company stated that the African health ministry selected the ART100 based on its performance in U.S. hospitals and its capability to strengthen national emergency and critical care infrastructure.
Inspira Technologies indicated that deliveries will continue throughout 2025 under a nationwide roll-out schedule, with installation, training, and onboarding to follow shipments.
The Israel-based medical device company specializes in respiratory support and blood monitoring solutions and is also developing the INSPIRA ART500, a next-generation oxygenation system, and HYLA, a non-invasive blood sensor platform. The stock has shown strong momentum with a 22% year-to-date return, though investors should note its high volatility with a beta of 2.3. For comprehensive analysis and additional insights, consider exploring InvestingPro, which offers exclusive financial metrics and investment tools.
In other recent news, Inspira Technologies OXY B.H.N. Ltd. has secured a significant $22.5 million purchase order for its FDA-cleared ART100 system. The order comes from a privately held company outside the United States, with payment expected in 2025. Additionally, Inspira Technologies is in discussions with a foreign government to potentially integrate the ART100 system into national emergency infrastructure, reflecting the system’s growing international interest. In response to anticipated demand from a European governmental authority, the company is boosting production of the ART100 system.
Inspira Technologies has also engaged a specialized consulting firm to aid in its strategic expansion and partner engagement efforts. This move aims to accelerate commercial growth and enhance the company’s enterprise value. Furthermore, Inspira Technologies has filed a routine shelf registration statement with the U.S. Securities and Exchange Commission. This filing is part of a standard renewal process conducted every three years. These developments highlight Inspira Technologies’ ongoing efforts to expand its market presence and operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.